Don’t Miss These Cleveland Clinic Cancer Center Presentations at the 2019 ASH Annual Meeting & Exposition

Friday, Dec. 6

FRIDAY SATELLITE SYMPOSIA
12:30-4:30 p.m.
W308, Level 3

Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies
Chair: Betty K. Hamilton, MD

Saturday, Dec. 7

EDUCATION SESSION
9:30-11:00 a.m. & 4:00-5:30 p.m.
Chapin Theater (W320), Level 3

Myeloproliferative Neoplasms: Managing the Cup that Runneth Over
Beyond JAK-STAT: Novel Therapeutic Targets in Ph-negative MPN
Speaker: Aaron T. Gerds, MD, MS

ORAL SESSIONS
Session 621. Lymphoma — Genetic/Epigenetic Biology: Lymphoma Genomics and Mechanisms of Lymphomagenesis
7:30-7:45 a.m.
W230, Level 2
19 Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma
Co-Authors: Sarah L. Ondrejka, DO; Eric D. Hsi, MD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Prognostic Factors and Treatment Outcomes
8:15-8:30 a.m.
W304, Level 3
16 The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy
Presenter: Abby Statler, PhD, MPH

Session 508. Bone Marrow Failure: Redefining Biological Paradigms of Bone Marrow Failure and Its Treatment
9:30-9:45 a.m.
Tangerine 3 (WF3-4), Level 2
103 Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response
Co-Authors: Bhavuk Garg, PhD; Seth J. Corey, MD

10:45-11:00 a.m.
Tangerine 3 (WF3-4), Level 2
108 T-Cell Landscape of Immune Aplastic Anemia Reveals a Convergent Antigen-Specific Signature
Co-Authors: Cassandra M. Kerr, MS; Jaroslaw P. Maciejewski, MD, PhD

Session 732. Clinical Allogeneic Transplantation: Results: Alternative Donors, Novel Regimens
9:45-10:00 a.m.
W307, Level 3
146 No Engraftment Advantage After Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial
Co-Author: Rabi Hanna, MD

Session 311. Disorders of Platelet Number or Function: Clinical Insights into ITP and TTP
10:45-11:00 a.m.
W308, Level 3
90 Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations
Co-Author: Keith R. McCrae, MD

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: New Treatment Strategies
12:30-12:45 p.m.
Chapin Theater (W320), Level 3
177 A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Presenter: Mikkael A. Sekeres, MD, MS

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Conditioning Intensity in Allogeneic Transplantation — Does It Matter?
2:00-2:15 p.m.
W331, Level 3
253 Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients
Co-Author: Ronald Sobecks, MD

Session 732. Clinical Allogeneic Transplantation: Results: Outcomes
2:30-2:45 p.m.
W307, Level 3
261 Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR
Co-Author: Anjali S. Advani, MD

Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: CAR T Cells — Refining the Approach
3:00-3:15 p.m.
Tangerine 3 (WF3-4), Level 2
227 SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/Refractory CD22+ Acute Leukemia
Presenter: Anjali S. Advani, MD

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) — Results from Prospective Clinical Trials: Results from CAR T-Cell Trials
3:00-3:15 p.m.
Hall E2, Level 2
245 Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the U.S. Lymphoma CAR T Consortium
Co-Author: Brian T. Hill, MD

POSTER SESSIONS
5:30-7:30 p.m
Hall B, Level 2

Session 311. Disorders of Platelet Number or Function: Poster I
1066 African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura
Co-Author: Keith R. McCrae, MD

1076 The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey
Co-Author: Keith R. McCrae, MD

Session 321. Blood Coagulation and Fibrinolytic Factors: Poster I
1104 Restore the Secretion and Activity of Factor VIII Mutants by Proteostasis Regulator
Presenter: Wei Wei, MD, PhD

1105 Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography
Co-Author: Keith R. McCrae, MD

Session 322. Disorders of Coagulation or Fibrinolysis: Poster I
1130 Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
Co-Author: Anne T. Neff, MD

Session 331. Pathophysiology of Thrombosis: Poster I
1143 Cancer-Associated Thrombosis Is Associated with Higher Mortality Across All Khorana Score Risk Levels
Presenter: Alok A. Khorana, MD

Session 503. Clonal Hematopoiesis: Aging and Inflammation: Poster I
1200 TET2 Loss Accelerates Leukemogenesis by Disrupting Mismatch Repair Proteins
Presenter: Ashwin Kishtagari, MBBS

Session 508. Bone Marrow Failure: Poster I
1226 Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving After Solid Organ and Hematopoietic Stem-Cell Transplantation
Presenter: Hassan Awada, MD

Session 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
1270 Can Monosomy 7 Be Targeted by Next-Generation Cereblon-Modulating Agents?
Presenter: Vera Adema, PhD

1279 Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 Without Cytotoxicity
Presenter: Ashwin Kishtagari, MBBS

1281 CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/del(7q)
Presenter: Vera Adema, PhD

Session 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster I
1302 Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Co-Authors: Caitlin Siebenaller, PharmD; Anjali S. Advani, MD

Session 614. Acute Lymphoblastic Leukemia: Therapy, Excluding Transplantation: Poster I
1344 Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial by Baseline CD22 Positivity Assessed by Local Laboratories
Co-Author: Anjali S. Advani, MD

Session 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
1404 Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?
Presenter: Hassan Awada, MD

1405 Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia
Presenter: Hassan Awada, MD

1406 Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis
Presenter: Hassan Awada, MD

1448 Predicting Minimal Residual Disease in Acute Myeloid Leukemia Through Stochastic Modeling of Clonality
Co-Author: Seth J. Corey, MD

Session 621. Lymphoma — Genetic/Epigenetic Biology: Poster I
1499 Higher Stability of Mutant mRNA as Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma
Co-Author: Eric D. Hsi, MD

Session 622. Lymphoma Biology — Non-Genetic Studies: Poster I
1515 Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab
Presenter: Neetha Parameswaran, PhD

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma — Clinical Studies: Poster I
1525 Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Presenter: Brian T. Hill, MD

Session 625. Lymphoma: Pre-Clinical — Chemotherapy and Biologic Agents: Poster I
1572 Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T- and B-Cells and a Patient-Derived Xenograft Model of Coexisting T- and B-Cell Proliferations
Presenter: Xiaoxian Zhao, PhD

Session 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) — Results from Prospective Clinical Trials: Poster I
1583 Characteristics and Outcomes of Patients Who Did Not Develop CRS After Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the U.S. Lymphoma CAR T Consortium
Co-Author: Brian T. Hill, MD

Session 636. Myelodysplastic Syndromes — Basic and Translational Studies: Poster I
1703 Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets
Presenter: Cassandra M. Kerr, MS

Session 637. Myelodysplastic Syndromes — Clinical Studies: Poster I
1715 Long-Term Follow-Up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Co-Author: Mikkael A. Sekeres, MD, MS

1716 How Morphologic Features Are Shaped by Underlying Somatic Genotype in MDS
Presenter: Yasunobu Nagata, MD, PhD

Session 642. CLL: Therapy, Excluding Transplantation: Poster I
1751 Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Co-Author: Brian T. Hill, MD

1756 Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Co-Author: Brian T. Hill, MD

Session 653. Myeloma: Therapy, Excluding Transplantation: Poster I
1838 Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis
Presenter: Nathaniel Rosko, PharmD

1841 Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Co-Author: Rajshekhar Chakraborty, MD

Session 704. Immunotherapies: Poster I
1948 Inotuzumab Ozogamicin Post-Transplant for Acute Lymphoblastic Leukemia
Co-Authors: Ronald Sobecks, MD; Navneet S. Majhail, MD, MS; Betty K. Hamilton, MD; Matt Kalaycio, MD; Aaron T. Gerds, MD, MS

Session 803. Emerging Diagnostic Tools and Techniques: Poster I
2089 Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes Using Artificial Intelligence
Co-Authors: Mikkael A. Sekeres, MD, MS; Sudipto Mukherjee, MD, PhD, MPH; Jacob Shreve, MD, MS; Rachel Shirley; Vera Adema, PhD; Hassan Awada, MD; Anjali S. Advani, MD; Cassandra M. Kerr, MS; Yasunobu Nagata, MD, PhD; Yihong Guan, PhD; Teodora Kuzmanovic, BA; Metis Hasipek, PhD7; Babal K. Jha, PhD; Jaroslaw P. Maciejewski, MD, PhD; Aziz Nazha, MD

2091 A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia Using Artificial Intelligence
Presenter: Jacob Shreve, MD, MS

Sunday, Dec. 8

SCIENTIFIC PROGRAM
7:30-9:00 a.m. & 4:30-6:00 p.m.
Valencia D (W415D), Level 4
My Metabolism and Myelopoiesis
Chair: Seth Corey, MD

HOW I TREAT SESSION
11:15 a.m.-12:15 p.m.
Bayhill 17 (Hyatt Regency Orlando)
Bringing Science to Clinical Dilemmas
Defining Treatment Strategies for MDS/MPN Overlap Syndromes
Speaker: Aaron Gerds, MD, MS

GENERAL SESSION
2:00-4:00 p.m.
Hall D, Level 2
Plenary Scientific Session
4 Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic
Co-Author: Keith R. McCrae, MD

SPOTLIGHT SESSION
4:30-6:00 p.m.
W312, Level 3
Point-Counterpoint: Curative Therapies for SCD — Does It Make More Sense to Target the Root Cause than All the Downstream Events
Speaker: Yogen Saunthararajah, MD

EDUCATION SESSION
4:30-6:00 p.m.
Hall E1, Level 2
Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia
Chair: Mikkael Sekeres, MD, MS

ORAL SESSIONS
Session 903. Health Services Research — Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies
8:00-8:15 a.m.
W307, Level 3
381 Are Racial Disparities in Acute Myeloid Leukemia Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Presenter: Abby Statler, PhD, MPH

Session 642. CLL: Therapy, Excluding Transplantation: Combination and Novel Treatment
8:45-9:00 a.m.
Hall E1, Level 2
360 A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Co-Authors: Brian T. Hill, MD; Ashley Morrison

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) — Results from Retrospective/Observational Studies: Population-Based Outcomes
9:30-9:45 a.m.
W224, Level 2
397 The Evaluation and Treatment of Burkitt Lymphoma in the Modern Era: Real-World Outcomes and Prognostication across 26 U.S. Academic Centers
Co-Authors: Deepa Jagadeesh, MD, MPH; Agrima Mian, MBBS, MD

10:45-11:00 a.m.
W224, Level 2
402 Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma and Central Nervous System Involvement Treated in the Modern Era: a Multi-Institutional Real-World Analysis
Co-Authors: Deepa Jagadeesh, MD, MPH; Yusra Shao, MD

Session 508. FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults
12:15-12:30 p.m.
Tangerine 3 (WF3-4), Level 2
452 FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults
Presenter: Jibran Durran

Session 508. Bone Marrow Failure: Emerging Treatment Strategies and Clinical Insights in Bone Marrow Failure
12:30-12:45 p.m.
Tangerine 3 (WF3-4), Level 2
453 Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function that Contributes to Hematopoietic Precursor Expansion
Presenter: Yihong Guan, PhD

Session 642. CLL: Therapy, Excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL
5:15-5:30 p.m.
Hall D, Level 2
502 Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Co-Authors: Brian T. Hill, MD; Allison M. Winter, MD

POSTER SESSIONS
6:00-8:00 p.m.
Hall B, Level 2

Session 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
2226 Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small-Molecule Factor D Inhibitor Danicopan (ACH-4471) in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

Session 331. Pathophysiology of Thrombosis: Poster II
2423 Mice Deficient in ß2-Glycoprotein I Have a Delayed Time to Thrombosis
Co-Author: Keith R. McCrae, MD

Session 502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Poster II
2472 Reversible TET Inhibitor as a Hematopoietic Stem Cell Booster: a Novel Strategy to Improve Stem Cell Function
Presenter: Sunisa Kongkiatkamon

Session 508. Bone Marrow Failure: Poster II
2499 Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria
Presenter: Hassan Awada, MD

Session 602. Disordered Gene Expression in Hematologic Malignancy, Including Disordered Epigenetic Regulation: Poster II
2525 Homeobox Transcription Factor Hhex Promotes Myeloid Leukemia in Cooperation with Mutant ASXL1
Co-Authors: Valeria Visconte, PhD; Jaroslaw P. Maciejewski, MD, PhD

Session 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
2553 Fatty Acid Binding Protein FABP5: a Novel Therapeutic Target in Acute Myeloid Leukemia
Presenter: Metis Hasipek, PhD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
2595 A Single-Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Presenter: Sudipto Mukherjee, MD, PhD, MPH

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster II
2650 A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Co-Author: Anjali S. Advani, MD

2651 SEL120 — a First-in-Class CDK8/19 Inhibitor as a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome — Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial
Co-Author: Aziz Nazha, MD

Session 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
2690 High E-Selectin Ligand Expression Contributes to Chemotherapy Resistance in Poor-Risk Relapsed and Refractory Acute Myeloid Leukemia Patients and Can Be Overcome with the Addition of Uproleselan
Co-Author: Anjali S. Advani, MD

2696 RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
Presenter: Christina A. Snider, BA

2716 Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Presenter: Sanghee Hong, MD

2720 Impact and Outcomes of RAS Gene Mutations in Core Binding Factor Acute Myeloid Leukemia
Presenter: Hassan Awada, MD

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) — Results from Retrospective/Observational Studies: Poster II
2891 Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning
Co-Authors: Eric D. Hsi, MD; Yong Li, PhD

Session 636. Myelodysplastic Syndromes — Basic and Translational Studies: Poster II
2984 Patient-Derived Xenografts Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia
Co-Author: Mikkael A. Sekeres, MD, MS

2992 Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
Presenter: Yasunobu Nagata, MD, PhD

Session 637. Myelodysplastic Syndromes — Clinical Studies: Poster II
2999 Luspatercept Significantly Reduces Red Blood Cell Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients with LR-MDS Enrolled in the MEDALIST Trial
Co-Author: Mikkael A. Sekeres, MD, MS

Session 642. CLL: Therapy, Excluding Transplantation: Poster II
3048 Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multicenter Study
Co-Author: Brian T. Hill, MD

Session 653. Myeloma: Therapy, Excluding Transplantation: Poster II
3148 External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma Patients
Co-Authors: Jack Khouri, MD; Christy J. Samaras, DO; Faiz Anwer, MD; Alex V. Mejia Garcia, MD; Dana E. Angelini, MD; Beth M. Faiman, PhD, CNP; Janice Reed, RN; Mary Ann Karam, RN; Kristen Schlueter, RN; Saveta Mathur, CNP; Kimberly Hamilton, APRN/PA; Nathaniel Rosko, PharmD; Jason Valent, MD

3150 Comparative Efficacy and Safety of Once- Versus Twice-Weekly Carfilzomib-Based Therapies in Relapsed Refractory Multiple Myeloma — a Systematic Review
Co-Authors: Tariq Iqtidar Sadiq Syed, MD; Faiz Anwer, MD

Session 636. Myelodysplastic Syndromes — Basic and Translational Studies: Poster II
2985 Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors
Presenter: Vera Adema, PhD

Session 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II
3264 Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness After Hematopoietic Cell Transplantation
Presenter: Fatima I. Adhi, MD

Session 903. Health Services Research — Malignant Conditions (Myeloid Disease): Poster II
3433 Identifying Factors that Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine-Based Therapies
Presenter: Caitlin Siebenaller, PharmD

Session 904. Outcomes Research — Non-Malignant Conditions: Poster II
3458 Clinical Outcomes of Cancer-Associated Thrombosis Beyond 6 Months of Anticoagulation
Co-Authors: Alok A. Khorana, MD; Mailey L. Wilks, CNP, MSN, APRN; Vicki Pinkava, MSBS, PA-C; Meghan O’Brien, MS, ANP-BC; Barbara Tripp, CNS; Jung-Min Song, RN, CNS; Keith R. McCrae, MD; Dana E. Angelini, MD

Session 905. Outcomes Research — Malignant Conditions (Lymphoid Disease): Poster II
3483 Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Co-Author: Brian T. Hill, MD

Session 906. Outcomes Research — Malignant Conditions (Myeloid Disease): Poster II
3499 Real-World Treatment Patterns and Transfusion Burden Among U.S. Patients with Newly Diagnosed Myelodysplastic Syndromes
Presenter: Sudipto Mukherjee, MD, PhD, MPH

Monday, Dec. 9

SPECIAL INTEREST SESSION
7:00-8:30 a.m.
Tangerine 2 (WF2), Level 2
Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults
Chair: Mikkael Sekeres, MD, MS
Speaker: Sudipto Mukherjee, MD, PhD, MPH

TRAINEE DIDACTIC SESSION
12:15-1:15 p.m.
W314, Level 3
Trainee Didactic Session 3: How to Set Up a Health Services and Outcomes Research Program
Speaker: Navneet S. Majhail, MD, MS

EDUCATION SESSIONS
7:00-8:30 a.m. & 2:45-4:15 p.m.
W331, Level 3
Bone Marrow Failure and Clonal Evolution
Diagnosis of Bone Marrow Failure Versus Hypocellular MDS in Older Adults
Speaker: Jaroslaw P. Maciejewski, MD, PhD

2:45-4:15 p.m.
Hall E2, Level 2
Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia
Chair: Mikkael Sekeres, MD, MS

ORAL SESSIONS
Session 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: The Impact of Epigenetic Therapies
7:30-7:45 a.m.
W307, Level 3
537 Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine
Presenter: Xiaorong Gu, PhD

Session 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies
7:45-8:00 a.m.
W304EFGH, Level 3
556 A Phase 2a Study of the LSD1 Inhibitor Img-7289 (Bomedemstat) for the Treatment of Myelofibrosis
Co-Author: Aaron T. Gerds, MD, MS

8:00-8:15 a.m.
W304EFGH, Level 3
557 A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
Presenter: Aaron T. Gerds, MD, MS

Session 636. Myelodysplastic Syndromes — Basic and Translational Studies: Mechanisms and Potential Therapeutic Targets in MDS
8:15-8:30 a.m.
W311ABCD, Level 3
564 Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia
Presenter: Valeria Visconte, PhD

Session 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
10:30-10:45 a.m.
W304EFGH, Level 3
667 Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Presenter: Aaron T. Gerds, MD, MS

Session 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects
10:30-10:45 a.m.
W304EFGH, Level 3
697 Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research
Co-Author: Betty K. Hamilton, MD

Session 637. Myelodysplastic Syndromes — Clinical Studies: Targeting Gene Mutations in MDS
10:30-10:45 a.m.
W311ABCD, Level 3
673 Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes, Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
Co-Author: Hetty E. Carraway, MD, MBA

Session 331. Pathophysiology of Thrombosis: Cancer-Associated and Pediatric Thrombosis
11:00-11:15 a.m.
Valencia BC (W415BC), Level 4
633 Extended Mutational Profiling by MSK-IMPACT Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy
Co-Author: Alok A. Khorana, MD

Session 637. Myelodysplastic Syndromes — Clinical Studies: Targeting Gene Mutations in MDS
11:15-11:30 a.m.
W311ABCD, Level 3
676 Phase 2 Results of APR-246 and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia
Co-Author: Mikkael A. Sekeres, MD, MS

11:45 a.m.-12:00 p.m.
W311ABCD, Level 3
678 Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes
Co-Authors: Mikkael A. Sekeres, MD, MS; Aziz Nazha, MD

Session 906. Outcomes Research — Malignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid Diseases
11:15-11:30 a.m.
Valencia D (W415D), Level 4
706 Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant: A Report from the Center for International Blood and Marrow Transplant Research
Co-Author: Betty K. Hamilton, MD

Session 613. Acute Myeloid Leukemia: Clinical Studies: Treatment of Relapsed/Refractory Disease
2:45-3:00 p.m.
Tangerine 3 (WF3-4), Level 2
733 Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia Patients
Co-Author: Anjali S. Advani, MD

Session 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) — Results from Retrospective/Observational Studies: Cellular Therapies
2:45-3:00 p.m.
W230, Level 3
763 Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the U.S. Lymphoma CAR T Consortium
Co-Author: Brian T. Hill, MD

Session 636. Myelodysplastic Syndromes — Basic and Translational Studies: RNA Processing and Signatures in MDS
2:45-3:00 p.m.
Tangerine 2 (WF2), Level 2
769 The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma — Clinical Studies: Mantle Cell Lymphoma: Frontline and Relapsed Therapies
3:15-3:30 p.m.
Hall D, Level 2
753 Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Co-Author: Brian T. Hill, MD

3:30-3:45 p.m.
754 KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Results of the Phase 2 ZUMA-2 Study
Co-Author: Brian T. Hill, MD

Session 731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders
3:45-4:00 p.m.
W311ABCD, Level 3
785 Does Addition of Rituximab to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation?
Presenter: Deepa Jagadeesh, MD, MPH

Session 704. Immunotherapies II
4:00-4:15 p.m.
Chapin Theater (W320), Level 3
780 Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
Co-Authors: Brian T. Hill, MD; Agrima Mian, MBBS, MD

Session 637. Myelodysplastic Syndromes — Clinical Studies: Lower-Risk MDS and CMML
4:30-4:45 p.m.
W311ABCD, Level 3
841 Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes with Ring Sideroblasts Who Require Red Blood Cell Transfusions
Co-Author: Mikkael A. Sekeres, MD, MS

Session 637. Myelodysplastic Syndromes — Clinical Studies: Lower-Risk MDS and CMML
4:45-5:00 p.m.
W311ABCD, Level 3
842 Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study — an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

Session 637. Myelodysplastic Syndromes — Clinical Studies: Lower-Risk MDS and CMML
5:15-5:30 p.m.
W311ABCD, Level 3
844 TET Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated by the AGMT Study Group
Co-Authors: Jaroslaw P. Maciejewski, MD, PhD; Bhumika J. Patel, MD

Session 802. Chemical Biology and Experimental Therapeutics: Functional Genomics and High-Throughput Screening
5:15-5:30 p.m.
W311EFGH, Level 3
880 TET Dioxygenase Inhibition as a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
Presenter: Yihong Guan, PhD

5:30-5:45 p.m.
W311EFGH, Level 3
881 Therapeutic Application of a Unique Calcium Channel Blocker to Target SF3B1 MDS
Presenter: Sunisa Kongkiatkamon

POSTER SESSIONS
6:00-8:00 p.m
Hall B, Level 2

Session 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III
3514 A Phase 2 Open-Label Study of Danicopan (ACH‑0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to Eculizumab Monotherapy
Co-Author: Jaroslaw P. Maciejewski, MD, PhD

Session 102. Regulation of Iron Metabolism: Poster III
3534 Iron Catalyzed Hydrogen Sulfide and Its Prevalence During Oxidative Events in Sickle Cell Disease
Co-Author: Yogen Saunthararajah, MD

Session 321. Blood Coagulation and Fibrinolytic Factors: Poster III
3621 High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice
Co-Author: Keith R. McCrae, MD

Session 331. Pathophysiology of Thrombosis: Poster III
3643 Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients
Presenter: Ann S. Kim, BA

3648 Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade
Co-Authors: Alok A. Khorana, MD; Pauline Funchain, MD; Keith R. McCrae, MD; Joanna Roopkumar, MBBS, MPH

3651 Molecular Subtyping to Predict Risk of Venous Thromboembolism in Patients with Advanced Lung Adenocarcinoma: A Cohort Study
Co-Authors: Alok A. Khorana, MD; Nathan A. Pennell, MD, PhD; Keith R. McCrae, MD

Session 332. Anticoagulation and Antithrombotic Therapy: Poster III
3683 Risk of Intracerebral Hemorrhage with and without Anticoagulation in Patients with Brain Metastasis: the Cleveland Clinic Experience
Presenter: Tariq Zuheir Kewan, MD

Session 508. Bone Marrow Failure: Poster III
3737 Expression of Human SBDSR126T in Sbds Null Background Shows Eif6 Dysregulation: An Adult Zebrafish Model for Shwachman-Diamond Syndrome
Presenter: Usua Oyarbide Cuervas-Mons, PhD, MSc, BSc

3743 Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential
Presenter: Jibran Durrani

3750 Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia
Presenter: Hassan Awada

3752 Effect of the Unfolded Protein Response and Oxidative Stress on Mutagenesis of CSF3R: a Model of Evolution of Severe Congenital Neutropenia to Myelodysplastic Syndrome/Acute Myeloid Leukemia
Presenter: Adya Sapra, MS

Session 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
3836 Determinants of “Fitness” for Intensive Therapy Among Acute Myeloid Leukemia Patients
Presenter: Abby Statler, PhD, MPH

Session 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster III
3909 The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Co-Author: Wei Wei, MD, PhD

3916 Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Co-Author: Mikkael A. Sekeres, MD, MS

3920 First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
Co-Author: Aziz Nazha, MD

Session 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma — Clinical Studies: Poster III
3982 Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multicenter Analysis
Presenter: Allison M. Winter, MD

3997 Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma

Co-Author: Brian T. Hill, MD

4004 Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multicenter Outcomes Analysis
Presenter: Rachel Hu, MD

Session 624. Hodgkin Lymphoma and T/NK Cell Lymphoma — Clinical Studies: Poster III
4027 Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A U.S. Multicenter Retrospective Analysis
Co-Authors: Rachel Hu, MD; Brian T. Hill, MD

Session 634. Myeloproliferative Syndromes: Clinical: Poster III
4175 Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)
Co-Author: Aaron T. Gerds, MD, MS

4190 Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study
Presenter: Aaron T. Gerds, MD, MS

Session 635. Myeloproliferative Syndromes: Basic Science: Poster III
4214 Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib
Co-Author: Aaron T. Gerds, MD, MS

Session 636. Myelodysplastic Syndromes — Basic and Translational Studies: Poster III
4216 Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms
Co-Authors: Mikkael A. Sekeres, MD, MS; Kathryn Guinta; Yogen Saunthararajah, MD

4221 Molecular Dissection of Del(5q): Distinction Between Primary and Secondary Del(5q) and Pathogenetic Implications
Presenter: Vera Adema, PhD

4233 ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
Presenter: Teodora Kuzmanovic

Session 637. Myelodysplastic Syndromes — Clinical Studies: Poster III
4238 Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
Presenter: Cameron Beau Hilton, BA

4243 Hematologic Improvement–Neutrophil and –Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes with Ring Sideroblasts Who Require Red Blood Cell Transfusions
Co-Author: Mikkael A. Sekeres, MD, MS

4271 Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Co-Authors: Jaroslaw P. Maciejewski, MD, PhD; Mikkael A. Sekeres, MD, MS

Session 641. CLL: Biology and Pathophysiology, Excluding Therapy: Poster III
4286 The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy
Co-Author: Brian T. Hill, MD

Session 651. Myeloma: Biology and Pathophysiology, Excluding Therapy: Poster III
4359 Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma
Presenter: Rajshekar Chakraborty, MD

Session 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster III
4442 Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies
Presenter: Faiz Anwer, MD

Session 704. Immunotherapies: Poster III
4452 Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
Presenter: Agrima Mian, MBBS, MD

Session 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III
4516 Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease
Co-Author: Betty K. Hamilton, MD

Session 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III
4557 Epigenomic Signatures in Myelodysplastic Syndrome Patients as Predictors of Donor Compatibility and Transplant Outcome
Co-Author: Aziz Nazha, MD

4567 Targeted Treatment and Survival Following Relapse After Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
Presenter: Sanghee Hong, MD

Session 732. Clinical Allogeneic Transplantation: Results: Poster III
4581 Timing for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia: A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT
Co-Author: Aziz Nazha, MD

4599 Interactions Between Donor Activating Killer Immunoglobulin-Like Receptors and Somatic Mutations in Association with Outcomes After Allogeneic Hematopoietic Cell Transplant for AML
Presenter: Sanghee Hong, MD

Session 901. Health Services Research — Non-Malignant Conditions: Poster III
4669 Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer-Associated Thrombosis
Co-Author: Alok A. Khorana, MD

Session 903. Health Services Research — Malignant Conditions (Myeloid Disease): Poster III
4747 Diagnostic Testing Patterns and Concordance with World Health Organization Criteria for Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS) in the Connect MDS/AML Registry
Co-Author: Mikkael A. Sekeres, MD, MS

4750 Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis
Presenter: Aaron T. Gerds, MD, MS